Taglich Brothers Initiates Coverage of DARA BioSciences, Inc.

Strategic Insights -

DARA BioSciences, Inc. is a development-stage company based in Raleigh, NC, that acquires high-potential therapeutic molecules and medical technologies from pharmaceutical companies and academic institutions. The company focuses on taking these product candidates through clinical development and regulatory review submissions, after which they are licensed or acquired by pharmaceutical companies. DARA currently has two drug candidates, KRN5500 and DB959, in its portfolio, with approved Investigational New Drug applications (INDs) from the FDA. The company has established partnerships with major pharmaceutical companies, including Bayer, Kyowa Hakko Kirin Co., and Nuada, LLC.

Key Takeaways:

  • DARA BioSciences, Inc. is a development-stage company that acquires high-potential therapeutic molecules and medical technologies from pharmaceutical companies and academic institutions.
  • The company undertakes further clinical development of acquired product candidates to a point where they can be sold or licensed to pharmaceutical companies.
  • DARA has two drug candidates, KRN5500 and DB959, both with approved INDs from the FDA.
  • KRN5500 has completed a Phase 2a trial, while DB959 has completed a Phase 1 study.
  • DARA's portfolio includes potential therapies for multiple sclerosis, Alzheimer's, and autoimmune disorders.
  • The company has licenses to metabolic disease treatments from Bayer, pain and central peripheral nervous system conditions from Kyowa Hakko Kirin Co., and DPP-IV inhibitors for the treatment of type 2 diabetes and other metabolic diseases from Nuada, LLC.

Statistics:

  • DARA BioSciences, Inc. was initiated coverage by Taglich Brothers, Inc. on January 12, 2011.
  • The company has two drug candidates in its portfolio, both with approved INDs from the FDA.
  • KRN5500 has completed a Phase 2a trial, with a target market of 500,000 individuals with neuropathic pain in cancer patients.
  • DB959 has completed a Phase 1 study, with a target market of 10 million individuals with type 2 diabetes.

Sources:

  • Marketwire, "Taglich Brothers, Inc. Initiates Coverage of DARA BioSciences, Inc.", January 12, 2011.
  • DARA BioSciences, Inc., SEC Filings, as of November 2010.
  • Taglich Brothers, Inc. Confidential Report, "DARA BioSciences, Inc.", November 2010.